Pantheon International reported an unaudited NAV per share of 510.7p as at 30 September 2025, unchanged from the prior month. The Company generated £27.6 million in net portfolio cash flow, with £39.7 million of distributions exceeding £12.1 million of capital calls...
GSK has received FDA approval for Blenrep (belantamab mafodotin-blmf) with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least two prior therapies...
Zotefoams has appointed Jack Clarke as an independent Non-Executive Director effective 28 October 2025. Clarke, formerly CFO of Essentra and Marshalls, brings extensive strategy and finance experience and will join the Audit, Nomination and Remuneration Committees...
Touchstone Exploration has conditionally raised £6.32 million through a private placement of 57.5 million new shares at 11 pence each. The Company may raise an additional £0.68 million via a retail offer to existing shareholders...
Pantheon International reported an unaudited NAV per share of 510.7p as at 30 September 2025, unchanged from the prior month. The Company generated £27.6 million in net portfolio cash flow, with £39.7 million of distributions exceeding £12.1 million of capital calls...
GSK has received FDA approval for Blenrep (belantamab mafodotin-blmf) with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least two prior therapies...
Zotefoams has appointed Jack Clarke as an independent Non-Executive Director effective 28 October 2025. Clarke, formerly CFO of Essentra and Marshalls, brings extensive strategy and finance experience and will join the Audit, Nomination and Remuneration Committees...
Touchstone Exploration has conditionally raised £6.32 million through a private placement of 57.5 million new shares at 11 pence each. The Company may raise an additional £0.68 million via a retail offer to existing shareholders...
